Moreover, Coxsackievirus A21 paired with pembrolizumab regulated PD-L1+ tumor cells in a phase Ib trial [130] (Fig. 8), whereas the combination of TG4010 (a modified vaccinia virus) with PD-1/PD-L1 inhibitors improved outcomes in advanced NSCLC patients in phase III research [131]. This evidence concerns the gene CD274 and neoplasm.